ALL BLOGS BY

Jacinta Flattery-O'Brien PhD

Jacinta is a trusted and recognised leader in biotech/pharma patenting, identified as an "IP Star" by the highly regarded Managing Intellectual Property Journal (MIP) for her expertise.

See Jacinta's full profile

Clinical trial information can invalidate an Australian patent

by Jacinta Flattery-O'Brien PhD, Naomi Pearce | Jan 15, 2021

On 5 November 2020, the High Court of Australia refused a special leave application by Mylan Health Pty Ltd to appeal...

Pharmaceutical patentees beware – the Australian Patent Office lays down the law on patent term extensions!

by Jacinta Flattery-O'Brien PhD, Naomi Pearce | Sep 18, 2020

The Australian Patent Office, in Ono Pharmaceutical Co., Ltd. et al [2020] APO 43, has emphatically confirmed that a...

Self-knowledge, narcissism, and accessibility of Australia’s patent system

by Jacinta Flattery-O'Brien PhD | Aug 11, 2020

His scholarship focuses on philosophy and the history of ideas. His published works include: “Plotinus, Self and the...